Company profile: Cytogel Pharma
1.1 - Company Overview
Company description
- Provider of biopharmaceutical pain treatments with reduced side effects, including CYT-1010, a novel pain relief drug entering Phase 2 clinical development demonstrating reduced addiction potential and less risk of respiratory depression; endomorphins, a new class for pain management showing potential for safer, more effective options; and patented biocompatible polymer hydrogels for improved drug delivery and medical device coatings.
Products and services
- Hydrogels for Drug Delivery: Patented, biocompatible polymer assemblies that enhance drug delivery performance and serve as coatings for medical devices
- Endomorphins: New-class analgesic products engineered for pain management, showing potential for safer, more effective treatment options with reduced side effects
- CYT-1010: Phase 2 clinical-stage analgesic product delivering pain relief with reduced addiction potential and lower risk of respiratory depression versus traditional treatments
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cytogel Pharma
NeuroCycle Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D focused on sub-type selective GABA-A modulation, including a lead candidate (NCT10004) that selectively targets a newly identified mechanism of action to reduce itch to near-baseline levels across models, including allergic and contact dermatitis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuroCycle Therapeutics company profile →
Eliem Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology treatments for nervous system disorders, including ETX-155, an investigational oral neuroactive steroid GABAA receptor positive allosteric modulator for major depressive disorder and focal onset seizures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eliem Therapeutics company profile →
Victory Pharma
HQ: United States
Website
- Description: Provider of prescription pharmaceutical products through acquisition, marketing, and development as a specialty pharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Victory Pharma company profile →
MDoloris
HQ: France
Website
- Description: Provider of medical equipment and monitoring solutions to soothe, lessen, monitor and assess patients' pain and its impact, including ANI Monitor V2, ANI MOC-9 and HFVI MOC-9 modules for Masimo Root to measure autonomic nervous system responses, NIPETM for neonatal parasympathetic evaluation in NICU settings, and a Web academy on ANI technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MDoloris company profile →
Electromedical Technologies
HQ: United States
Website
- Description: Provider of pain relief to improve global wellness by relieving chronic and acute pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Electromedical Technologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cytogel Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cytogel Pharma
2.2 - Growth funds investing in similar companies to Cytogel Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cytogel Pharma
4.2 - Public trading comparable groups for Cytogel Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →